GGT5 Is an Independent Prognostic Biomarker in Stomach Adenocarcinoma

Table 1

Relationship between expression of GGT5 and clinicopathological characteristics.

Characteristic	Low expression of GGT5	High expression of GGT5
n	187	188
T stage, n (%)
T1	17 (4.6%)	2 (0.5%)	<0.001
T2	48 (13.1%)	32 (8.7%)
T3	73 (19.9%)	95 (25.9%)
T4	45 (12.3%)	55 (15%)
N stage, n (%)
N0	59 (16.5%)	52 (14.6%)	0.173
N1	48 (13.4%)	49 (13.7%)
N2	42 (11.8%)	33 (9.2%)
N3	29 (8.1%)	45 (12.6%)
M stage, n (%)
M0	166 (46.8%)	164 (46.2%)	1.000
M1	13 (3.7%)	12 (3.4%)
Pathologic stage, n (%)
Stage I	39 (11.1%)	14 (4%)	0.002
Stage II	50 (14.2%)	61 (17.3%)
Stage III	67 (19%)	83 (23.6%)
Stage IV	21 (6%)	17 (4.8%)
Gender, n (%)
Female	69 (18.4%)	65 (17.3%)	0.718
Male	118 (31.5%)	123 (32.8%)
Age, n (%)
≤65	71 (19.1%)	93 (25.1%)	0.049
>65	112 (30.2%)	95 (25.6%)
Age, median (IQR)	69 (59, 75)	66 (57, 72)	0.013